Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Napolitano

Showing results (1-10 of 99) with videos related to

Pageof 10
Sort By:
Ebiomedicine|January 8, 2019
Splicing molecular biology and novel therapies in diffuse malignant peritoneal mesotheliomaAndrea Napolitano
Trends in Cancer|June 13, 2017
Malignant Mesothelioma: Time to Translate?Andrea Napolitano, Michele Carbone
British Journal of Cancer|February 23, 2019
Secondary KIT mutations: the GIST of drug resistance and sensitivityAndrea Napolitano, Bruno Vincenzi
Ebiomedicine|February 10, 2019
PDGFRα inhibition in soft-tissue sarcomas: Have we gotten it all wrong?Andrea Napolitano, Bruno Vincenzi
JAMA Dermatology|November 13, 2015
Concerns About Presence of a Wild-Type BAP1 Allele in Absence of Nuclear Protein ExpressionAndrea Napolitano, Michele Carbone
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
First-Line Tyrosine Kinase Inhibitors in Soft-Tissue Sarcomas: A Role for Anlotinib?Andrea Napolitano, Paul H Huang, Robin L Jones
Cancers|January 11, 2025
Novel Therapeutics in Soft Tissue SarcomaLeonidas Mavroeidis, Andrea Napolitano, Paul Huang, et al.
Rare Tumors|February 19, 2024
Real-world evidence for ultra rare cancersLeonidas Mavroeidis, Andrea Napolitano, Paul Huang, et al.
BMJ Case Reports|June 5, 2019
Unexpected benefit from an 'old' metronomic chemotherapy regimen in advanced chordomaMariella Spalato Ceruso, Andrea Napolitano, Marianna Silletta, et al.
Cancers|December 9, 2023
Reply to Chen, A.; Zhang, X. Comment on "Golčić et al. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours. <i>Cancers</i> 2023, <i>15</i>, 4081"Marin Golčić, Robin L Jones, Paul Huang, et al.
Pageof 10

Showing results (1-10 of 99) with videos related to

Sort By:
Pageof 10
Ebiomedicine|January 8, 2019
Splicing molecular biology and novel therapies in diffuse malignant peritoneal mesotheliomaAndrea Napolitano
Trends in Cancer|June 13, 2017
Malignant Mesothelioma: Time to Translate?Andrea Napolitano, Michele Carbone
British Journal of Cancer|February 23, 2019
Secondary KIT mutations: the GIST of drug resistance and sensitivityAndrea Napolitano, Bruno Vincenzi
Ebiomedicine|February 10, 2019
PDGFRα inhibition in soft-tissue sarcomas: Have we gotten it all wrong?Andrea Napolitano, Bruno Vincenzi
JAMA Dermatology|November 13, 2015
Concerns About Presence of a Wild-Type BAP1 Allele in Absence of Nuclear Protein ExpressionAndrea Napolitano, Michele Carbone
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
First-Line Tyrosine Kinase Inhibitors in Soft-Tissue Sarcomas: A Role for Anlotinib?Andrea Napolitano, Paul H Huang, Robin L Jones
Cancers|January 11, 2025
Novel Therapeutics in Soft Tissue SarcomaLeonidas Mavroeidis, Andrea Napolitano, Paul Huang, et al.
Rare Tumors|February 19, 2024
Real-world evidence for ultra rare cancersLeonidas Mavroeidis, Andrea Napolitano, Paul Huang, et al.
BMJ Case Reports|June 5, 2019
Unexpected benefit from an 'old' metronomic chemotherapy regimen in advanced chordomaMariella Spalato Ceruso, Andrea Napolitano, Marianna Silletta, et al.
Cancers|December 9, 2023
Reply to Chen, A.; Zhang, X. Comment on "Golčić et al. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours. <i>Cancers</i> 2023, <i>15</i>, 4081"Marin Golčić, Robin L Jones, Paul Huang, et al.
Pageof 10